Jeffrey Hampton
Payments from drug & device makers
Across 240 payments — averaging $19.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Novo Nordisk$893
- Kowa Pharmaceuticals America, Inc.$516
- AstraZeneca$440
- Bayer$347
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$341
- plus $1K from 15 others
What the payments were for
- Food & beverage$4,713100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 62 | $1,067 |
| Novo Nordisk | 54 | $893 |
| Kowa Pharmaceuticals America, Inc. | 23 | $516 |
| AstraZeneca | 14 | $440 |
| Bayer | 19 | $347 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 12 | $341 |
| Lilly USA, LLC | 13 | $212 |
| Otsuka America Pharmaceutical, Inc. | 9 | $194 |
| Lundbeck LLC | 4 | $113 |
| Abbott | 4 | $91 |
| Boehringer Ingelheim | 4 | $81 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $79 |
| Amgen(2 entities) | 5 | $73 |
| Johnson & Johnson | 3 | $73 |
| Pfizer | 3 | $57 |
| GSK | 2 | $39 |
| Dexcom, Inc. | 1 | $29 |
| Astellas Pharma US Inc | 1 | $29 |
| Mylan Specialty L.p. | 1 | $15 |
| Insulet Corporation | 1 | $13 |
| Axsome Therapeutics, Inc. | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,713 in reported general payments places this provider in the 90th percentile of 6,706 family providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 147 | $107,198 |
| JardianceEmpagliflozin | 116 | $84,423 |
| JanuviaSitagliptin Phosphate | 69 | $55,224 |
| OzempicSemaglutide | 55 | $54,124 |
| MounjaroTirzepatide | 41 | $53,428 |
| RexultiBrexpiprazole | 33 | $47,094 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 64 | $46,316 |
| XareltoRivaroxaban | 51 | $35,986 |
| VraylarCariprazine Hcl | 24 | $33,524 |
| FarxigaDapagliflozin Propanediol | 35 | $28,410 |
| TrulicityDulaglutide | 13 | $25,298 |
| Repatha SureclickEvolocumab | 43 | $25,102 |
| LinzessLinaclotide | 27 | $19,977 |
| RybelsusSemaglutide | 19 | $17,957 |
| EntrestoSacubitril/Valsartan | 23 | $15,937 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $57 | $107,198147 claims |
| Boehringer IngelheimJardiance, Combivent Respimat, Tradjenta | $81 | $105,828149 claims |
| Lilly USA, LLCMounjaro, Trulicity | $212 | $78,72654 claims |
| Novo NordiskOzempic, Rybelsus | $893 | $72,08174 claims |
| AbbVieVraylar, Linzess | $1,067 | $53,50051 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $39 | $52,03676 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $194 | $47,09433 claims |
| Johnson & JohnsonXarelto | $73 | $35,98651 claims |
| AstraZenecaFarxiga | $440 | $28,41035 claims |
| BayerKerendia | $347 | $14,18616 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $79 | $12,45625 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 6,706 family providers in Tennessee.
Other family in Halls
- Stacy BrownMt Juliet$719K
- Dana WebberKnoxville$499K
- Brandy BiedermanHixson$448K
- Cynthia MillerMurfreesboro$384K
- Tamera ThoenerNashville$254K
- April SwonerHermitage$246K
- Jennifer WilliamsNashville$213K
- Chantil JeffreysGermantown$195K
- Laura PorchCordova$148K
- Lori LankfordNashville$148K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.